64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

NCT04868604 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms, Castration-Resistant

Interventions

DRUG: 64Cu-SAR-bisPSMA
DRUG: 67Cu-SAR-bisPSMA

Sponsor

Clarity Pharmaceuticals Ltd